Primary Sclerosing Cholangitis (PSC) Epidemiology Forecast 2025-2034

A systematic review indicates that the incidence rates for primary sclerosing cholangitis (PSC) range from 0 to 1.3 per 100,000 people per year, while prevalence rates range from 0 to 16.2 per 100,000 people. According to PSC Partners, a non-profit organization that provides support and education to PSC patients, approximately 1 in every 10,000 people worldwide is diagnosed with PSC. Primary sclerosing cholangitis (PSC) epidemiology forecast suggests that the median age at diagnosis is 41 years, with the condition more prevalent in men, who make up 65% to 70% of primary sclerosing cholangitis cases.

Primary Sclerosing Cholangitis (PSC) Epidemiology Forecast Report Coverage

The “Primary Sclerosing Cholangitis (PSC) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of primary sclerosing cholangitis (PSC). It projects the future incidence and prevalence rates of primary sclerosing cholangitis (PSC) cases across various populations. The study covers age and type as major determinants of the primary sclerosing cholangitis (PSC) population. The report highlights patterns in the prevalence of primary sclerosing cholangitis (PSC) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on primary sclerosing cholangitis (PSC) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Primary Sclerosing Cholangitis (PSC) Understanding: Disease Overview

Primary sclerosing cholangitis (PSC) refers to a rare liver disease that affects the bile ducts (the tubes that carry bile from the liver to the intestines). The condition is characterized by the inflammation and damage to the bile ducts, which can result in scarring. This scarring can gradually lead to the bile ducts becoming narrow or even closing off completely, causing bile to build up in the liver. Primary sclerosing cholangitis (PSC) can cause liver damage and, in severe cases, liver failure.

Primary sclerosing cholangitis (PSC) is often linked to an autoimmune response and inflammatory bowel diseases like ulcerative colitis. Common symptoms include fatigue, itching, jaundice (yellowing of the skin and eyes), and abdominal pain. However, some people with primary sclerosing cholangitis (PSC) may not show symptoms for many years.

Primary Sclerosing Cholangitis (PSC) Epidemiology Perspective

The primary sclerosing cholangitis (PSC) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for primary sclerosing cholangitis (PSC) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The primary sclerosing cholangitis (PSC) detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to a nationwide, population-based study by Crothers, Hannah et al. (England, 2015-2027), the prevalence of primary sclerosing cholangitis (PSC) in 2020 was 7.6 per 100,000 people and 8.6 when including inflammatory bowel disease (IBD) that developed after PSC. The annual percentage change in prevalence was 8.8%. By 2027, the expected prevalence of PSC with IBD was estimated to be 11.7, and 13.3 when considering IBD developing after PSC, with an annual percentage change of 6.4%
• Approximately 1 in every 10,000 people worldwide is diagnosed with primary sclerosing cholangitis (PSC), according to PSC Partners, a non-profit organization providing support and education to PSC patients, families, and caregivers.
• Primary sclerosing cholangitis (PSC) is frequently observed in individuals with inflammatory bowel disease (IBD), predominantly in those with ulcerative colitis (UC), although it can also be associated with Crohn's disease. It is estimated that more than 75% of primary sclerosing cholangitis patients are diagnosed with ulcerative colitis.
• Patients are typically diagnosed with primary sclerosing cholangitis (PSC) between the ages of 30 and 40, with the median age at diagnosis being 41 years. PSC is more prevalent in men, who account for 65% to 70% of cases. Studies show that males have a 2-fold higher risk of developing PSC compared to females.

Country-wise Primary Sclerosing Cholangitis (PSC) Epidemiology Segment

The primary sclerosing cholangitis (PSC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of primary sclerosing cholangitis (PSC) varies significantly between countries due to differences in factors such as genetic predisposition, the prevalence of associated conditions like inflammatory bowel disease (IBD), access to healthcare, diagnostic capabilities, and awareness of the condition. Further, variations in dietary habits, lifestyle factors, and the incidence of other diseases, such as autoimmune disorders, also impact the epidemiology of primary sclerosing cholangitis (PSC) in different regions. In the United States, more than 30,000 people are affected by primary sclerosing cholangitis, as per PSC Partners.

Primary Sclerosing Cholangitis (PSC): Treatment Overview

Primary sclerosing cholangitis (PSC) therapeutics help in managing the symptoms, slowing the progression of the disease, and improving the quality of life. Ursodeoxycholic acid (UDCA) is one of the commonly used drugs that aids in improving bile flow in the liver.

In cases where primary sclerosing cholangitis is linked to autoimmune responses, immunosuppressive drugs are prescribed to reduce inflammation and prevent further damage. Medications like cholestyramine or antihistamines are given to patients who experience severe itching (pruritus). For individuals with advanced primary sclerosing cholangitis (PSC) or liver failure, a liver transplant may be necessary.

Key Questions Answered

• What are the key findings of primary sclerosing cholangitis (PSC) epidemiology in the 8 major markets?
• What will be the total number of patients with primary sclerosing cholangitis (PSC) across the 8 major markets during the forecast period?
• What was the country-wise primary sclerosing cholangitis (PSC) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of primary sclerosing cholangitis (PSC) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of primary sclerosing cholangitis (PSC) during the forecast period of 2025-2034?
• What are the currently available treatments in the primary sclerosing cholangitis (PSC) market?
• What are the disease risks, signs, symptoms, and unmet needs of primary sclerosing cholangitis (PSC)?

Scope of the Primary Sclerosing Cholangitis (PSC) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of primary sclerosing cholangitis (PSC) based on several factors.
• The Primary Sclerosing Cholangitis (PSC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The primary sclerosing cholangitis (PSC) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.